February 21, 2017 – Raleigh, NC

Dr. Anjani Jha, founder and CEO of MAA Laboratories, will join several other biotechnology executives to discuss the current status and the future of life science innovations. The discussion panel, titled “Life Science Companies Changing the World,” will be held on Thursday, February 28 as part of the Council for Entrepreneurial Development (CED) Life Science Conference at the Raleigh Convention Center. The CED Life Science Conference is a leading life science conference in the nation. The conference is designed to showcase highly innovative life science companies based in North Carolina and connect these companies to a diverse group of venture capital and corporate investors.

About MAA Laboratories Inc.
MAA Laboratories Inc. is a specialty pharmaceutical company located in the Research Triangle Park region of North Carolina. MAA has developed the NanoCont^TM drug development platform as a broadly applicable solution for addressing a variety of drug delivery and development challenges. Our company is dedicated to using the NanoCont^TM technology to create advanced medicines that improve patients’ lives by addressing unmet clinical needs in a variety of therapeutic areas, including oncology, neurological, and cardiovascular diseases.

The NanoCont^TM drug development platform
MAA Laboratories’ NanoCont^TM technology is a broadly applicable drug development solution for improving the clinical performance of poorly soluble pharmaceuticals. Aspects of drug performance that can be improved by the NanonCont^TM technology include: increased therapeutic efficiency, enhanced targeted drug delivery, elimination of food effects, increased oral bioavailability, reduced intra- and inter-patient variability, and/or mitigated undesirable side effects. This technology can be used to reformulate marketed products in a manner that resolves known drug performance liabilities and creates new intellectual property protection. For investigational compounds, the NanoCont^TM technology can be used to overcome hurdles related to low solubility and poor bioavailability to ensure consistent dosing and facilitating the development of promising pipeline compounds.

Contact MAA Laboratories
For inquiries related to product licensing and development partnerships, please contact our business development team at BD@maalaboratories.com.

For press and other inquiries, please contact:

Corporate Office
MAA Laboratories, Inc.
400 Park Offices Drive
Suite# 214
Durham, NC 27709
United States of America
Email: info@maalaboratories.com
Phone: 919.271.7868